Trending Now
Jaguar Health Inc. (NASDAQ:JAGX) Subsidiary Napo Pharmaceuticals Announces the Filing of...
Covid-19 has touched everyone across the globe because if you are not infected, you are affected. People and businesses are becoming helpless and distressed...
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
Wall Street eyes TLT (NASDAQ:TLT) short
I hope everyone had a restful Thanksgiving and that you’re ready to ride the bulls ?
TLT (NASDAQ:TLT) is...
MAKE IT MODERN
LATEST REVIEWS
Sorrento Therapeutics Inc (NASDAQ: SRNE) Incorporates Sorrento Mexico Ltd In Mexico...
COFEPRIS granted emergency use approval for Sorrento Therapeutics Inc (NASDAQ: SRNE)’s COVI-STIX under OFICIO: CAS/10720/2021.
On June 14, 2021, Sorrento received an import permit from...
MAKE IT MODERN
PERFORMANCE TRAINING
Titan Pharmaceuticals Inc.’s (NASDAQ:TTNP) Partner Enters Exclusive Commercialization agreement For Probuphine In EU with...
Titan Pharmaceuticals Inc. (NASDAQ:TTNP) has announced that it's Molteni Farmaceutici partner has signed an exclusive commercialization agreement with Accord Healthcare for Sixmo®, which is...
Mereo BioPharma Group (NASDAQ:MREO) Inks a Pact With Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) to Develop...
Mereo BioPharma Group (NASDAQ:MREO) entered a collaboration accord and license pact with Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) for the development of setrusumab. As...
Vaccinex (NASDAQ:VCNX) Announce Pepinemab Study Results in HD And Enters clinical collaboration Deal With...
Vaccinex Inc. (NASDAQ:VCNX) has announced its second phase double-blind, placebo-controlled SIGNAL study of its experimental clinical treatment for Huntington's diseases, pepinemab, which did not...
Kadmon Holdings Inc. (NASDAQ: KDMN) Announces Q2 2021 Results And REZUROCK Updates in cGVHD...
Kadmon Holdings Inc. (NASDAQ: KDMN) has reported its Q2 2021 financial results and offered operational updates.
REZUROCK approved for cGVHD
The company announced that the US...
Dynavax Technologies Corporation (NASDAQ:DVAX) Reports Record HEPLISAV-B® Vaccine Net Revenue Of $11.6 Million In...
Dynavax Technologies Corporation (NASDAQ:DVAX) has reported Q3 2020 financial results in which it posted a record HEPLISAV-B® net revenue of $11.6 million since its...
MAKE IT MODERN
